Retatrutide

Retatrutide is an investigational peptide classified as a GLP-1/GIP/Glucagon triple agonist. This means it is designed to activate the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. It is currently not FDA-approved for any indication and is categorized as unregulated, meaning its sale and distribution are not subject to the same controls as approved pharmaceuticals. It is also not currently on the list of substances banned from compounding. Our trust score for Retatrutide is 77.5/100, a B+ grade, reflecting a balance between promising research and potential safety concerns.

The mechanism of action of Retatrutide involves mimicking the effects of naturally occurring hormones that regulate blood sugar and appetite. By activating the GLP-1 and GIP receptors, it stimulates insulin release and reduces glucagon secretion, leading to improved blood glucose control. The activation of the glucagon receptor, in addition to the GLP-1 and GIP receptors, is hypothesized to further enhance weight loss by increasing energy expenditure and promoting fat breakdown. This triple agonist approach is designed to offer a more comprehensive metabolic effect compared to single or dual agonist therapies.

The research landscape surrounding Retatrutide is active, with 136 research papers and 34 clinical trials currently listed. Several Phase 3 trials sponsored by Eli Lilly and Company are underway, investigating its efficacy and safety in various populations. The TRIUMPH-Outcomes trial (n=10000) is evaluating the effect of Retatrutide on cardiovascular and kidney outcomes in adults living with obesity. The SYNERGY-Outcomes trial (n=4500) is examining its effects in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). Other Phase 3 trials are focusing on participants with obesity or overweight (n=2300) and those with obesity and cardiovascular disease (n=1800). A further trial, TRANSCEND-T2D-2 (n=1250), is comparing Retatrutide with semaglutide in adults with type 2 diabetes. These trials are crucial for determining the long-term safety and efficacy of Retatrutide. Key research papers include reviews in *Nutrients*, *Liver International*, and *Current Diabetes Reports* that discuss the role of anti-obesity medications and the targeting of specific pathways in metabolic disorders.

Regarding safety, our current safety score for Retatrutide is 65.0/100. FDA adverse event data shows 14 total reports, none classified as serious. The most common reported reactions include abdominal pain, increased heart rate, intentional product misuse, nausea, and product advertising issues. It is important to note that this data is limited and may not fully represent the potential risks associated with Retatrutide use, especially in the absence of comprehensive, long-term safety data from completed clinical trials.

Currently, Retatrutide is primarily used by individuals seeking weight loss and body composition improvements. Given its unregulated status, access is typically through research settings or online vendors, which carries inherent risks due to the lack of regulatory oversight. Its potential benefits are being explored for individuals with obesity, overweight, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease.

The ongoing Phase 3 clinical trials will provide critical data on the efficacy and safety profile of Retatrutide, which will ultimately determine its regulatory fate and potential future availability as a treatment option.